MA53898B1 - Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament - Google Patents
Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicamentInfo
- Publication number
- MA53898B1 MA53898B1 MA53898A MA53898A MA53898B1 MA 53898 B1 MA53898 B1 MA 53898B1 MA 53898 A MA53898 A MA 53898A MA 53898 A MA53898 A MA 53898A MA 53898 B1 MA53898 B1 MA 53898B1
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazin
- ylmethyl
- medicine
- morpholine derivatives
- nr2b
- Prior art date
Links
- JKLJHSTZIZURSR-UHFFFAOYSA-N 4-(pyrazin-2-ylmethyl)morpholine Chemical class C=1N=CC=NC=1CN1CCOCC1 JKLJHSTZIZURSR-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Abstract
La présente invention concerne de nouvelles 4-pyrazin-2-ylméthyl-morpholines de formule générale a, des procédés pour leur préparation, des compositions pharmaceutiques les contenant et leur utilisation en thérapie, en particulier dans le traitement ou la prévention d'états associés à des propriétés de modulation allostérique négative de nr2b.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18200943 | 2018-10-17 | ||
PCT/EP2019/078027 WO2020079039A1 (fr) | 2018-10-17 | 2019-10-16 | Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation en tant que médicament |
Publications (2)
Publication Number | Publication Date |
---|---|
MA53898A MA53898A (fr) | 2022-01-26 |
MA53898B1 true MA53898B1 (fr) | 2023-03-31 |
Family
ID=63878518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA53898A MA53898B1 (fr) | 2018-10-17 | 2019-10-16 | Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament |
Country Status (35)
Country | Link |
---|---|
US (2) | US11166958B2 (fr) |
EP (1) | EP3867244B1 (fr) |
JP (1) | JP7093468B2 (fr) |
KR (1) | KR20210079325A (fr) |
CN (1) | CN112888685B (fr) |
AR (1) | AR116711A1 (fr) |
AU (1) | AU2019362330B2 (fr) |
BR (1) | BR112021004993A2 (fr) |
CA (1) | CA3113308A1 (fr) |
CL (1) | CL2021000858A1 (fr) |
CO (1) | CO2021004612A2 (fr) |
CR (1) | CR20210184A (fr) |
DK (1) | DK3867244T3 (fr) |
DO (1) | DOP2021000069A (fr) |
EA (1) | EA202191014A1 (fr) |
EC (1) | ECSP21027009A (fr) |
ES (1) | ES2940184T3 (fr) |
FI (1) | FI3867244T3 (fr) |
HR (1) | HRP20230249T1 (fr) |
HU (1) | HUE061891T2 (fr) |
IL (1) | IL282142B2 (fr) |
JO (1) | JOP20210075A1 (fr) |
LT (1) | LT3867244T (fr) |
MA (1) | MA53898B1 (fr) |
MX (1) | MX2021004418A (fr) |
PE (1) | PE20211278A1 (fr) |
PH (1) | PH12021550834A1 (fr) |
PL (1) | PL3867244T3 (fr) |
PT (1) | PT3867244T (fr) |
RS (1) | RS63988B1 (fr) |
SA (1) | SA521421756B1 (fr) |
SG (1) | SG11202103806VA (fr) |
SI (1) | SI3867244T1 (fr) |
TW (1) | TWI828779B (fr) |
WO (1) | WO2020079039A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113950478B (zh) * | 2019-06-04 | 2024-02-02 | 勃林格殷格翰国际有限公司 | 作为nr2b负向调节剂的嘌呤衍生物及其作为药物的用途,特别是用于治疗抑郁病症 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6495561B2 (en) | 1999-10-29 | 2002-12-17 | Merck & Co., Inc. | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists |
AU2002338334B8 (en) | 2001-04-03 | 2008-09-18 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists |
ES2312603T3 (es) | 2001-07-24 | 2009-03-01 | Richter Gedeon Nyrt | Derivados de piperidina como antagonistas del receptor nmda. |
JP2009518409A (ja) * | 2005-12-06 | 2009-05-07 | メルク エンド カムパニー インコーポレーテッド | モルホリンカルボキサミドプロキネチシン受容体アンタゴニスト |
WO2010088414A2 (fr) * | 2009-01-28 | 2010-08-05 | Emory University | Potentialisateurs du récepteur nmda, sélectifs pour des sous-unités, et destinés au traitement d'états neurologiques |
WO2012128582A2 (fr) | 2011-03-23 | 2012-09-27 | Hyundai Pharm Co., Ltd. | Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant |
EP2909180B1 (fr) | 2012-10-18 | 2016-10-05 | F. Hoffmann-La Roche AG | Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5 |
CN106255679B (zh) * | 2014-02-27 | 2019-09-06 | 默克专利有限公司 | 用作nav通道抑制剂的杂环化合物及其用途 |
WO2016029146A1 (fr) | 2014-08-22 | 2016-02-25 | University Of Washington | Inhibiteurs spécifiques de la méthionyl-tarn synthétase |
US10501451B2 (en) * | 2015-10-14 | 2019-12-10 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
-
2019
- 2019-10-16 PE PE2021000513A patent/PE20211278A1/es unknown
- 2019-10-16 FI FIEP19786343.4T patent/FI3867244T3/fi active
- 2019-10-16 ES ES19786343T patent/ES2940184T3/es active Active
- 2019-10-16 JO JOP/2021/0075A patent/JOP20210075A1/ar unknown
- 2019-10-16 MX MX2021004418A patent/MX2021004418A/es unknown
- 2019-10-16 US US16/654,030 patent/US11166958B2/en active Active
- 2019-10-16 PL PL19786343.4T patent/PL3867244T3/pl unknown
- 2019-10-16 HU HUE19786343A patent/HUE061891T2/hu unknown
- 2019-10-16 KR KR1020217014924A patent/KR20210079325A/ko unknown
- 2019-10-16 SG SG11202103806VA patent/SG11202103806VA/en unknown
- 2019-10-16 MA MA53898A patent/MA53898B1/fr unknown
- 2019-10-16 IL IL282142A patent/IL282142B2/en unknown
- 2019-10-16 HR HRP20230249TT patent/HRP20230249T1/hr unknown
- 2019-10-16 AU AU2019362330A patent/AU2019362330B2/en active Active
- 2019-10-16 PT PT197863434T patent/PT3867244T/pt unknown
- 2019-10-16 CA CA3113308A patent/CA3113308A1/fr active Pending
- 2019-10-16 CN CN201980067936.7A patent/CN112888685B/zh active Active
- 2019-10-16 EP EP19786343.4A patent/EP3867244B1/fr active Active
- 2019-10-16 LT LTEPPCT/EP2019/078027T patent/LT3867244T/lt unknown
- 2019-10-16 AR ARP190102937A patent/AR116711A1/es unknown
- 2019-10-16 DK DK19786343.4T patent/DK3867244T3/da active
- 2019-10-16 SI SI201930465T patent/SI3867244T1/sl unknown
- 2019-10-16 JP JP2021520981A patent/JP7093468B2/ja active Active
- 2019-10-16 RS RS20230140A patent/RS63988B1/sr unknown
- 2019-10-16 TW TW108137247A patent/TWI828779B/zh active
- 2019-10-16 WO PCT/EP2019/078027 patent/WO2020079039A1/fr active Application Filing
- 2019-10-16 CR CR20210184A patent/CR20210184A/es unknown
- 2019-10-16 EA EA202191014A patent/EA202191014A1/ru unknown
- 2019-10-16 BR BR112021004993-2A patent/BR112021004993A2/pt unknown
-
2021
- 2021-04-07 CL CL2021000858A patent/CL2021000858A1/es unknown
- 2021-04-13 CO CONC2021/0004612A patent/CO2021004612A2/es unknown
- 2021-04-14 SA SA521421756A patent/SA521421756B1/ar unknown
- 2021-04-14 PH PH12021550834A patent/PH12021550834A1/en unknown
- 2021-04-16 DO DO2021000069A patent/DOP2021000069A/es unknown
- 2021-04-16 EC ECSENADI202127009A patent/ECSP21027009A/es unknown
- 2021-08-27 US US17/458,631 patent/US20210393644A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42239B1 (fr) | Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant | |
TN2014000147A1 (fr) | Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique | |
MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
MA42295B1 (fr) | Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation | |
MA54231B1 (fr) | Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine | |
MA45222B1 (fr) | Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
MA34308B1 (fr) | Triazolopyridines substituées | |
MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
MA38099A1 (fr) | Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4 | |
MA35422B1 (fr) | Imidazopyridazines amino-substituees | |
MA33450B1 (fr) | Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques | |
MA32035B1 (fr) | Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4 | |
TN2015000547A1 (fr) | Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1 | |
MA40769A (fr) | Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA40955B1 (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
MA35601B1 (fr) | Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1 | |
MA29411B1 (fr) | 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa | |
MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
MA33302B1 (fr) | 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale | |
MA30916B1 (fr) | Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine | |
MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
FR2939135B1 (fr) | Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique | |
MA54653B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
MA46342B1 (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation | |
MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique |